Is oestrogen neuroprotective?

Psychiatria Danubina

Volumn 21, Issue SUPPL. 1, 2009, Pages 120-127

  Agius, Mark ^a   Hockings, Helen ^b   Wilson, Charlotte ^c   Lane, Dan ^d  

^a UNIVERSITY OF CAMBRIDGE   (United Kingdom)

^b CLARE COLLEGE   (United Kingdom)

^c Leventis Foundation   (United Kingdom)

^d BEDFORD HOSPITAL   (United Kingdom)

Author keywords

At risk mental state; Neuro protection; Oestrogen; Prodrome; Schizophrenia

Indexed keywords

ACETYLCYSTEINE; ANTIDEPRESSANT AGENT; ANTIOXIDANT; CYCLOOXYGENASE 2 INHIBITOR; ERYTHROPOIETIN; ESTROGEN; ESTROGEN RECEPTOR ALPHA; ESTROGEN RECEPTOR BETA; GLYCINE; LITHIUM; MEMANTINE; NEUROLEPTIC AGENT; OMEGA 3 FATTY ACID; PLACEBO;

ALZHEIMER DISEASE; APOPTOSIS; CLINICAL TRIAL; CONFERENCE PAPER; DRUG MECHANISM; GENE EXPRESSION; HORMONE SUBSTITUTION; HUMAN; MENTAL HEALTH; NEUROPROTECTION; ONSET AGE; POSTMENOPAUSE; PROTEIN PROTEIN INTERACTION; PSYCHOSIS; SCHIZOPHRENIA;

ANTIPSYCHOTIC AGENTS; APOPTOSIS; BRAIN; DRUG THERAPY, COMBINATION; ESTRADIOL; ESTROGENS; FEMALE; HUMANS; MALE; NEUROPROTECTIVE AGENTS; SCHIZOPHRENIA; SCHIZOPHRENIC PSYCHOLOGY; SCHIZOTYPAL PERSONALITY DISORDER;

EID: 70350322370     PISSN: 03535053     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (54)

1. Ahokas A, Aito M, Turtiainen S. Association between oestradiol and puerperal psychosis. Acta Psychiatr Scand. 2000; 101:167-169
2. Archer JS. NAMS/Solvay Resident Essay Award. Relationship between estrogen, serotonin, and depression. Menopause 1999; 6:71-78
3. Behl, C. Neuroprotective effects of estrogens in the central nervous system: menachnisms of action. In: Häfner, H (Ed.), Risk and protective factors in schizophrenia, towards a conceptual model of the disease process. Steinkopff Verlag, Darmstadt Berlin Heidelberg New York 2002.
4. Berger G, Dell 'Olio M, Amminger P, Cornblatt B, Phillips L, Yung A, Yan Y, Berk M, McGorry P Neuroprotection in emerging psychotic disorders Early Intervention in Psychiatry 2007; 1: 114-127.
5. Behrens S, Hafner H, De Vry J, Gattaz WF. Estradiol attenuates dopamine-medicated behaviour in rats. Implications for sex differences in schizophrenia. Schizophr Res 1992; 6:114.
6. Chua WL, de Izquierdo SA, Kulkarni J, Mortimer A. Estrogen for schizophrenia. The Cochrane Database of Systematic Reviews2005. 4:Art. No.: CD004719. DOI: 10.1002/14651858. CD004719.pub2.
7. Clopton J, Gordon JH. In vivo effects of estrogen and 2-hydroxy estradiol on D-2 dopamine receptor agonist affinity states in rat striatum. J Neural Transm1986; 66:13-20.
8. Dalton, K, Menstruation and acute psychiatric illness. Br.Med.J 1959; 1, 148-149.
9. Di Paolo T, Payet P, Labrie F. Effect of prolactin and estradiol on rat striated dopamine receptors. Life Sci. 1982; 31:2921-2929. (Pubitemid 13212463)
10. Endo, M., Daiguji, M., Asano, Y., Yanashita, L, Lakahashi, S. Periodic psychosis occurring in association with the menstrual cycle. J. Clin. Psychiatry, 1978; 39, 456-461.
11. Gattaz, W.F., Behrens, S., De Vrie, J., Häfner, H. Östradiol hemmt Dopamin-vermittelte Verhaltensweisen bei Ratten - ein Tiermodell zur Untersuchung der geschlechtsspezifischen Unterschiede bei der Schizophrenie. Fortschr. Neurol. Psychiatr. 1992; 60, 8-16.
12. Fink, G. The psychoprotective action of estrogen is mediated by central serotonergic as well as dopaminergic mechanisms. In: Takada, A., Curzon, G. Eds.), Serotonin in the central nervous system and periphery. Elsevier Science, BV., Holland, pp. 175-187.1995.
13. Fink, G., Sumner, B., McQueen, J.K., Wilson, H., Rose, R. Sex steroid control of mood, mental state and memory. Clin. Exp. Pharmacol. Physiol. 1998; 25, 764-765.
14. Fink G, Sumner B, Rosie R, Wilson H, McQueen J. Androgen actions on central serotonin neurotransmission: relevance for mood, mental state and memory. Behav Brain Res. 1999; 105:53-68. (Pubitemid 29447612)
15. Fink G. Oestrogen-serotonin link: effects on mood, mental state and memory. Presentation at 1st World Congress on Women's Mental Health; March 27-31, 2001; Berlin, Germany.
16. Häfner, H., Riecher-Rössler, A.; Hambrecht M., Maurer, K., Meissner, S., Schmidtke, A., Fätkenheuer, B., Löffler, W., an der Heiden, W. IRAOS: an instrument for the assessment of onset and early course of schizophrenia. Schizophr. Res. 1992; 6:209-223.
17. Häfner H, Riecher A, Maurer K, Fatkenheuer B, Löffler W, an der Heiden W, et al. Sex differences in schizophrenic diseases. Geschlechtsunterschiede bei schizophrenen Erkrankungen. Fortschr Neurol Psychiatr. 1991; 59:343-360
18. Häfner H, Maurer K, Löffler W, an der Heiden W, Munk-Jörgensen P, Hambrecht M, et al. The ABC Schizophrenia Study: a preliminary overview of the results. Soc Psychiatry Psychiatr Epidemiol. 1998; 33:380-386
19. Häfner H Schizophrenia: Do men and women suffer from the same disease? Rev. psiquiatr. clín. 2002 vol.29 no.6:267-292.
20. Hafner H Prodrome, onset, and Early Course of Schizophrenia in The Epidemiology of Schizophrenia Murray RM, Jones PB, Susser E, vanOs J, Cannon M eds Cambridge University Press p124-147.2003.
21. Hallonquist, J.D., Seeman, M.V., Lang, M., Rector, N.A. Variaton in symptom severity over the menstural cycle of schizophrenics. Biol. Psychiatry 1993; 33, 207-209. (Pubitemid 23089970)
22. Huber JC, Schneeberger C, Tempfer CB. Genetic modelling of the estrogen metabolism as a risk factor of hormone-dependent disorders. Maturitas. 2002; 42:1-12. (Pubitemid 34521716)
23. Kulkarni, J., Fink, G., Hormones and psychoses. In: Castle, D.J., McGrath, J., Kulkarni, J. (Eds.), Women and schizophrenia. Cambridge University Press, Cambridge, pp. 51-66.2000.
24. Kulkarni, J., de Castella, A., Smith, D., Taffe, J., Keks, N., Copolov, D. A clinical trial of the effects of estrogen in acutely psychotic women. Schizophr. Res. 1996 20, 247-252.
25. Kulkarni, J., Gostt, K., de Castella, A., The menstrual cycle in women with schizophrenia. Schizophr. Res. 1996 18, 254.
26. Kulkarni, J., de Castella, A., Taffe, J., Burger, H., Reidel, A. Clinical estrogen trials in patients with schizophrenia. Current Opinion in Psychiatry 1999; 12(Suppl. 1), 184-185.
27. Kulkarni J, Riedel A, de Castella AR, Fitzgerald PB, Rolfe TJ, Taffe J, et al. Estrogen - a potential treatment for schizophrenia. Schizophr Res. 2001; 48:137-144
28. Kulkarni J. Clinical adjunctive trials of estrogen in women with schizophrenia. Presentation at 1st World Congress on Women's Mental Health; March 27-31, 2001; Berlin, Germany.
29. Kulkarni J. Gender differences in the quality of life of people with schizophrenia. Presentation at 1st World Congress on Women's Mental Health; March 27-31, 2001; Berlin, Germany.
30. Kulkarni, J. De Castella, A., Downey, M., Hammond, J., Reidel, A., Ward, S., White, S., Taffe, J., Fitzgerald, P., Burger, H., Clinical estrogen trials in schizophrenia. In: Häfner, H (Ed.), Risk and protective factors in schizophrenia, towards a conceptual model of the disease process. Steinkopff Verlag, Berlin Heidelberg New York Darmstadt. 2002.
31. Kulkarni J, de Castella A, Fitzgerald PB, Gurvich CT, l Bailey M, Bartholomeusz C, Burger H, Estrogen in Severe Mental Illness; A Potential New Treatment Approach Arch Gen Psychiatry 2008; 65(8):955-960.
32. Lindamer LA, Lohr JB, Harris MJ, Jeste DV. Gender, estrogen,and schizophrenia. Psychopharmacology Bulletin. 1997; 33:221-228
33. Lindamer LA, Buse DC, Lohr JB, Jeste DV. Hormone replacement therapy in postmenopausal women with schizophrenia: positive effect on negative symptoms? Biol Psychiatry. 2001; 49:47-51.
34. McDowall J Oestrogen Receptors 2003 Interpro Protein Archive.
35. Maurer K. Overview of the oestrogen protection hypothesis in schizophrenia (abstract S47). Archives of Women's Mental Health. 2001; 3(suppl 2):10.
36. Ma YJ, Hill DF, Creswick KE, Costa ME, Cornea A, Lioubin MN et al. Neuregulins signaling via a glial erbB-2-erbB-4 receptor complex contribute to the neuroendocrine control of mammalian sexual development. J Neurosci. 1999; 19:9913-9927 (Pubitemid 30226664)
37. McEwen, B.S., Biegen, A., Rainbow, T.C., Paden, C., Snyder, L., DeGroff, V., The interaction of estrogens with intracellular receptors and with putative neurotransmitter receptors: implications for the mechanisms of activation of regulation of sexual behaviour and ovulaton. In: Fuxe, K., Gustafsson, J.A., Wetterberg, L. (Eds.), Steroid hormone regulation of the brain. Pergammon Press, New York, pp. 15-29.1981.
38. McGorry P. Early psychosis -gender aspects of treatment. Presentation at 1st World Congress on Women's Mental Health; March 27-31, 2001; Berlin, Germany 2001.
39. Riecher-Rössler A, Häfner H. Schizophrenia and oestrogens -is there an association? Eur Arch Psychiatry Clin Neurosci. 1993; 242:323-328
40. Riecher-Rössler, A., Häfner, H., Stumbaum, M., Maurer, K., Schmidt, R., Can estradiol modulate schizophrenic symptomatology? Schizophr. Bull. 1994; 20, 203-214.
41. Riecher-Rössler, A., Häfner, H., Dütsch-Strobel, A., Oster, M., Stumbaum, M., van Gülick-Baller, M, Löffler, W. Further evidence for a specific role of estradiol in schizophrenia? Biol. Psychiatry 1994;36, 492-495.
42. Riecher-Rössler A. 1994 Die Spätschizophrenie - eine valide Entität? Eine empirische Studie zu Risikofaktoren, Krankheitsbild und Verlauf. Habilitationsschrift. Universität Heidelberg-Mannheim.
43. Riecher-Rössler A, Löffler W, Munk-Jörgensen P. What do we really know about late-onset schizophrenia? Eur Arch Psychiatry Clin Neurosci. 1997;247:195-208.
44. Riecher-Rössler A. Oestrogens and schizophrenia. Curr Opin Psychiatry2003; 187-192
45. Riecher-Rössler A. Estrogens and Schizophrenia. In: Bergemann N, Riecher-Rössler A. Oestrogen Effects in Psychiatric Disorders. Wien: Springer; 31-52.2005.
46. Riecher-Rössler A, de Geyter C The forthcoming role of treatment with oestrogens in mental health Swiss Med Wkly 2007; 137:565-572.
47. Seeman MV. Interaction of sex, age and neuroleptic dose. Compr Psychiatry. 1983; 24:125-128
48. Seeman, M.V., Cohen, R., Puberty and schizophrenia. In: Lopéz-Ibor, J.L., Sartorius, N., Gaebel, W., Haasen, C. (Eds.), Psychiatry on new thresholds. Abstracts of the XI World Congress of Psychiatry, Hamburg, Germany, 6-11 August, 1999, Vol.I.
49. (Current Opinion in Psychiatry, Vol. 12, Suppl. 1).
50. Sherwin B. Estrogen and cognitive functioning in postmenopausal women (abstract S228). Archives of Women's Mental Health 2001. 3(suppl 2):50.
51. Sumner, B.E.H., Fink, G. Oestradiol-17β in its positive feedback mode significantly increases 5-HT2a receptor density in the frontal, cingulate and piriform cortex of the female rat. J. Physiology 1995;483, 52.
52. Sumner, B.E.H., Grant, K.E., Rosie, R., Hegele-Hartung, C., Fritzemeier, K.-H., Fink, G., Effects of tamoxifen on serotonin transporter and 5-hydroxytryptamine2A receptor binding sites and mRNA levels in the brain of ovariectomized rats with or without acute estradiol replacement. Mol. Brain Res. 1999; 73, 119-128.
53. Shughrue, P.J., Lane, M.V., Merchenthaler, I. Comparative distribution of estrogen receptor and X and B MRNA in the rat central nervous system. J. Compr. Neurol. 1997; 388, 507-525.
54. Woolley, C.S., McEwen, B.S. Estradiol regulates hippocampal dendritic spine density via an N-Methyl-D-aspartate receptordependent mechanism. J. Neurosci 1994.14, 7680-7687.